Podcasts about Relativity

* A Whole Lot Moore: Peter W. Moor, ThD is a Christian master metallurgist listed as "inventor" in patents held by U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public. * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists! * E-PLat - (The Simhony/EPOLA): RSR is suggesting a name for the E-PLat!! Hear how Menahem Simhony is the father of a scientifically satisfactory description of what "space" is likely made of. Originally called the EPOLA, for the "Electron/Positron Lattice," we're suggesting E-PLat to avoid confusion with a certain virus! You'll have to listen to all 4 parts of the interview to form your opinion on whether or not the EPOLA/E-PLat makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe. * Deriving $10,000.00: ... and quite possibly a Nobel Prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constatn "G" based on the Natural Physics and Structure of the Simhony/EPOLA Model of the Space Vaccuum. (Pre-register this prize right here)

* A Whole Lot Moore: Peter W. Moor, ThD is a Christian master metallurgist listed as "inventor" in patents held by U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public. * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists! * E-PLat - (The Simhony/EPOLA): RSR is suggesting a name for the E-PLat!! Hear how Menahem Simhony is the father of a scientifically satisfactory description of what "space" is likely made of. Originally called the EPOLA, for the "Electron/Positron Lattice," we're suggesting E-PLat to avoid confusion with a certain virus! You'll have to listen to all 4 parts of the interview to form your opinion on whether or not the EPOLA/E-PLat makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe. * Deriving $10,000.00: ... and quite possibly a Nobel Prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constatn "G" based on the Natural Physics and Structure of the Simhony/EPOLA Model of the Space Vaccuum. (Pre-register this prize right here)  

In this episode, I'm guiding you through one of the most life altering shifts I've ever made - harnessing the Universal Law of Relativity.This has helped me to reframe experiences, elevate my energy and expand every aspect of my life.Relativity used to feel like the thief of joy whenever I scrolled, compared or judged. But after deep embodiment work and nervous system regulation, I now treat relativity as a superpower.I use it as a tool to reveal hidden growth, honour small wins and rewire my perspective for lasting abundance.If you're ready to stop measuring your worth against anyone else's timeline and start celebrating your own path... this is for you.Get ready for a fresh perspective on your wins, challenges and daily rituals.Join me today as I discuss…• The energetic mechanics of relativity and why every experience is neutral until you choose your lens• How comparison hijacks your dreams, and three simple practices to reclaim your power• A powerful “Then vs Now” journal ritual to anchor your personal benchmarks• Everyday embodiment exercises that turn mundane tasks into proof of your commitment to your dreamsLoved this episode? Please feel free to rate, review and subscribe

#365 In this episode of the Let It In podcast, Guy welcomed back Thomas Campbell for an insightful conversation on exploring other realities, consciousness, and the nature of life and death. Thomas shared his experiences of traversing different virtual realities, interacting with beings beyond Earth, and understanding the essence of consciousness. They discussed how consciousness grows through multiple lifetimes, the roles one can undertake in different realities, and how intent can alter future probabilities. Tom also touched on overcoming the fear of death and the importance of making low-entropy, love-based choices. He offered practical advice for those seeking to explore these concepts through his online resources and workshops. This episode delved deep into profound themes, resonating with both new listeners and longtime followers of Tom's work. About Thomas: Thomas W. Campbell is the author of Tom's Park and the My Big TOE trilogy that “unifies science and philosophy, physics and metaphysics, mind and matter, purpose and meaning, the normal and the paranormal”. The attributes assigned by some theologians to their concept of God are very similar to the attributes of the LCS, the larger consciousness system as scientifically derived by Tom.  Tom has said for over a decade that the next big cultural and scientific paradigm shift is virtual reality. Virtual reality is now a more widely accepted concept in science and technology. Tom combines a fundamental understanding of consciousness and virtual reality to back up this prediction with a logically and scientifically derived My Big TOE theory.  This theory explains most of the remaining big questions in both physics and metaphysics”. Tom's model of Consciousness derives Quantum Mechanics and Relativity, eliminates quantum weirdness, and builds a scientific foundation under much of what was previously deemed “paranormal”.  This comprehensive, logical, and scientific explanation of both objective and subjective reality perfectly defines a Big TOE. A former NASA physicist, Tom worked as a large complex systems analyst by day and collected evidential information in the larger consciousness system by night.  Tom delivers information through his unique abilities and experience that you will not find anywhere else. Key Points Discussed:  (00:00) - What He Sees Beyond This Reality Is MIND-BLOWING! Avatars, Death & Your Soul's Mission (01:12) - Introduction to the Podcast (04:22) - The Power of Intent and Connection (19:13) - Understanding Life and Death (41:22) - Exploring Other Realities (42:23) - Interacting with Other Realities (47:13) - Parallel Processing in Multiple Realities (50:17) - The Nature of Information and Consciousness (54:11) - Tom's Mission and Writing Journey (59:17) - Learning and Growing Through Experiences (01:08:40) - The Role of Love and Service in Consciousness (01:16:48) - Resources for Exploring Consciousness How to Contact Thomas Campbell:www.my-big-toe.comwww.facebook.com/TWCMBTmbtevents.comwww.youtube.com/user/twcjr44   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co

* Even Moore: Peter W. Moore, ThD is a Christian master metallurgist listed as "inventor" in patents held by Hughes Aircraft and U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public.    * E-Plat - (The Simhony/EPOLA): RSR is suggesting a name for the E-Plat!! Here how Menahem Simhony is the father of a scientifically satisfactory description of what "space" is likely made of. Originally called the EPOLA, for the "Electron/Positron Lattice," we're suggesting E-Plat to avoid confusion with a certain virus! You'll have to listen to all 4 parts of the interview to form your opinion on whether or not the E-Plat makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe.   * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists!    * Derive $10,000.00: ...and quite possibly a Nobel prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constant “G” based on the Natural Physics and Structure of the E-Plat Model of the Space Vacuum. (Pre-register this prize right here)

* Even Moore: Peter W. Moore, ThD is a Christian master metallurgist listed as "inventor" in patents held by U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public.    * E-Plat - (The Simhony/EPOLA): RSR is suggesting a name for the E-Plat!! Here how Menahem Simhony is the father of a scientifically satisfactory description of what "space" is likely made of. Originally called the EPOLA, for the "Electron/Positron Lattice," we're suggesting E-Plat to avoid confusion with a certain virus! You'll have to listen to all 4 parts of the interview to form your opinion on whether or not the E-Plat makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe.   * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists!    * Derive $10,000.00: ...and quite possibly a Nobel prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constant “G” based on the Natural Physics and Structure of the E-Plat Model of the Space Vacuum. (Pre-register this prize right here)

Have you ever looked around and thought, “I should be further along by now”? That comparison trap is something we all fall into — especially as women navigating the big transitions of midlife, like empty nest or retirement. But today, I want to offer you a powerful reframe through the lens of the Law of Relativity. In this episode, we'll explore how this universal law reminds us that nothing in life is inherently good or bad, ahead or behind — it only seems that way when we compare it to something else. I share a fresh take on self-image, the illusion of success, and how shifting our internal perspective can immediately shift how we feel about our journey. You'll learn why comparison distorts your truth, how to spot when you're misusing this law, and how to come back to center — where your unique strengths, divine timing, and purpose already exist. ✨ Here's what we cover in this episode: How to know when you're misusing the Law of Relativity A self-image example around aging that might just change how you see yourself What happens when you shift your comparisons inward instead of outward How to stop seeing yourself as behind — and start honoring where you are If you've ever felt discouraged by where you are in life or business, this episode will remind you: you're not behind — you're right on time.

Ever since Albert Einstein published his Special Theory of Relativity in 1905, one equation has been the bane of humans hoping to explore the stars: E=mc². In addition to informing our understanding of gravity, space, and time, this formula implies that traveling at or beyond light speed is impossible. And given how expansive the universe is, this speed limit severely restricts our ability to zip around the cosmos. But while most physics textbooks describe this speed limit, their explanations don't always tell the whole story.自从 1905 年阿尔伯特·爱因斯坦发表狭义相对论以来，一个方程一直是人类探索恒星的祸根：E=mc²。除了加深我们对重力、空间和时间的理解之外，这个公式还意味着以光速或超光速旅行是不可能的。考虑到宇宙有多么广阔，这个速度限制严重限制了我们绕宇宙飞行的能力。但是，虽然大多数物理教科书都描述了这个速度限制，但他们的解释并不总是能说明全部情况。In Einstein's equation, E stands for energy, m for mass, and c for a constant— specifically, the speed of light in a vacuum. C squared is a huge number, which means it requires enormous amounts of energy to move even small amounts of mass close to the speed of light. This relationship is why the only particles that can travel at light speed are those with no mass at all, such as photons.在爱因斯坦方程中，E 代表能量，m 代表质量，c 代表常数，特别是真空中的光速。 C平方是一个巨大的数字，这意味着即使是很小的质量也需要大量的能量才能接近光速。这种关系就是为什么唯一能够以光速传播的粒子是那些完全没有质量的粒子，例如光子。That's the short answer for why objects with mass can't reach or exceed light speed. But to make full use of Einstein's equation, physicists often include one more variable. This gamma represents the Lorentz Factor, which models how an object's velocity changes the way that object experiences time, length, and other physical properties. Now, when an object's velocity is a very small percentage of the speed of light, this variable resolves to 1, so it doesn't impact the equation. However, when an object is moving fast enough, this denominator drops to 0. Since dividing by 0 is impossible, this breaks the equation and makes the variables therein mathematically impossible— hence the unbreakable speed limit.这就是为什么有质量的物体无法达到或超过光速的简短答案。但为了充分利用爱因斯坦方程，物理学家通常会多加入一个变量。该伽马代表洛伦兹因子，它模拟物体的速度如何改变物体经历时间、长度和其他物理属性的方式。现在，当物体的速度只占光速的很小一部分时，该变量解析为 1，因此不会影响方程。然而，当物体移动得足够快时，该分母就会降至 0。由于除以 0 是不可能的，这会破坏方程并使得其中的变量在数学上不可能 - 因此是牢不可破的速度限制。But what does it actually mean for this math to break down? To answer that, we need to understand the physical system its modeling: spacetime. After Einstein published his theory of special relativity, his mentor Hermann Minkowski realized that— if his student was right— it would mean space and time were not two separate entities, but one connected system. And everything in the universe travels through space and time simultaneously. However, traveling through one of these vectors limits the speed at which we can travel through the other. To picture this, imagine moving north at a fixed speed. You could turn to travel east at the same speed, but moving northeast would mean you move in both directions more slowly. The tradeoffs are the same when we move through spacetime. Since our typical movement through space is so much slower than the speed of light, we mostly perceive moving through time at a relatively steady speed. But if an object managed to move through space at the speed of light, it would no longer move through time. This is the kind of time dilation charted by the Lorentz Factor, which models how time slows down for objects moving at incredibly high velocities.但这个数学模型崩溃到底意味着什么呢？为了回答这个问题，我们需要了解其建模的物理系统：时空。爱因斯坦发表狭义相对论后，他的导师赫尔曼·明可夫斯基意识到——如果他的学生是对的——那就意味着空间和时间不是两个独立的实体，而是一个相互联系的系统。宇宙中的一切事物都是同时穿越空间和时间的。然而，穿过这些矢量之一会限制我们穿过另一个矢量的速度。为了描绘这一点，想象一下以固定速度向北移动。您可以以相同的速度转向向东行驶，但向东北移动意味着您在两个方向上移动的速度都会更慢。当我们穿越时空时，权衡是相同的。由于我们在空间中的典型运动比光速慢得多，因此我们大多认为以相对稳定的速度在时间中运动。但如果一个物体能够以光速在空间中移动，它就不再能在时间中移动。这是洛伦兹因子绘制的时间膨胀类型，它模拟了以极高速度移动的物体的时间如何减慢。This nuance is just one of several hiding in E=mc². For example, the c in Einstein's equation refers specifically to the speed of light in a “vacuum,” which outer space approximates. But light's speed is actually defined by what it's traveling through. For example, when light travels through water, its speed is reduced by about 25%. And scientists can propel low mass particles like charged electrons through water at speeds faster than these photons. This means that underwater, some particles can travel faster than light; and doing so emits a ghostly blue glow known as Cherenkov radiation.这种细微差别只是 E=mc² 中隐藏的几个细微差别之一。例如，爱因斯坦方程中的 c 特指“真空”中的光速，即外层空间的近似值。但光速实际上是由它所穿过的物体决定的。例如，当光在水中传播时，其速度会降低约25%。科学家可以以比光子更快的速度推动带电电子等低质量粒子穿过水。这意味着在水下，一些粒子的运动速度可以超过光速；这样做会发出一种幽灵般的蓝色光芒，称为切伦科夫辐射。Despite these loopholes, the major takeaway of E=mc² remains true. As far as we know, we still can't travel faster than light in a vacuum. But this hasn't stopped scientists from theorizing what might happen if we did. If you were on a spacecraft approaching light speed, your vision would likely become kaleidoscopic. The direction your ship moved would appear blue-shifted, while the things next to and behind you would be red-shifted. And if you were somehow able to reach or exceed light speed, it might even manifest as some kind of time travel— potentially letting you chat with Einstein himself to rewrite our fundamental understanding of physics.尽管存在这些漏洞，E=mc² 的主要结论仍然正确。据我们所知，我们在真空中的行进速度仍然无法超过光速。但这并没有阻止科学家们对如果我们这样做会发生什么进行理论分析。如果你乘坐接近光速的宇宙飞船，你的视野可能会变得千变万化。你的船移动的方向会出现蓝移，而你旁边和后面的东西会红移。如果你能够以某种方式达到或超过光速，它甚至可能表现为某种时间旅行——有可能让你与爱因斯坦本人聊天，重写我们对物理学的基本理解。

Dr James Keaveney spoke to Mike Wills about the 120th anniversary of Einstein’s Theory of Relativity, what it meant then, why it still matters now, and how it continues to inform science at UCT, CERN, and beyond. Afternoon Drive with John Maytham is the late afternoon show on CapeTalk. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

sermon, "relativity" by Marcus Campbell from the Lewiston Church of Christ on June 29, 20225.

* A Whole Lot Moore: Peter W. Moore, PhD is a Christian master metallurgist listed as "inventor" in patents held by Hughes Aircraft and U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public.    * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists!    * Simhony/EPOLA: Menahem Simhony is the father of a scientifically satisfactory description of what space might be made of. And EPOLA means "Electron/Positron Lattice." You'll have to listen to all 4 parts of the interview to form your opinion on whether or not it makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe.   * Deriving $10,000.00: ...and quite possibly a Nobel prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constant “G” based on the Natural Physics and Structure of the Simhony/EPOLA Model of the Space Vacuum. (Pre-register this prize right here).

* A Whole Lot Moore: Peter W. Moore, PhD is a Christian master metallurgist listed as "inventor" in patents held by Hughes Aircraft and U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public.    * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists!    * Simhony/EPOLA: Menahem Simhony is the father of a scientifically satisfactory description of what space might be made of. And EPOLA means "Electron/Positron Lattice." You'll have to listen to all 4 parts of the interview to form your opinion on whether or not it makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe.   * Deriving $10,000.00: ...and quite possibly a Nobel prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constant “G” based on the Natural Physics and Structure of the Simhony/EPOLA Model of the Space Vacuum. (Pre-register this prize right here).  

The Daily Quiz - Science and Nature Today's Questions: Question 1: What is the word for a male weasel? Question 2: Who proposed The Theory of Relativity? Question 3: What is the name of the natural phenomenon that occurs when particles from the solar wind interact with gases in the atmosphere? Question 4: What type of oven did Percy Spencer invent after a magnetron melted his candy bar? Question 5: Who created an audiometer to detect vestigial hearing in the deaf, among other inventions? Question 6: As what is a camelopard also known? Question 7: The "canebrake", "timber" and "pygmy" are types of what" Question 8: What is the word for a group of sheep? Question 9: What is the name of the soil that is always frozen and helps to define the boundary of the Arctic? This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Sponsor Details:This episode is brought to you by NordVPN...your gateway to online security and safe browsing. Discover your special Space Nuts discount by visiting www.nordvpn.com/spacenuts for an exclusive offer!Time Dilation, Cosmic Questions, and the Nature of SpaceIn this enlightening episode of Space Nuts, hosts Heidi Campo and Professor Fred Watson dive into a captivating array of listener questions that explore the intricacies of time, light, and the universe itself. From the mysteries of dark matter to the philosophical implications of faster-than-light travel, this episode is a treasure trove of astronomical insights.Episode Highlights:- Speed of Light and Time Dilation: The episode kicks off with a thought-provoking inquiry from Martins in Latvia about why an object traveling at the speed of light ages differently than one on Earth. Fred unpacks the concept of time dilation as described in Einstein's theory of relativity, illustrating how time behaves differently for observers in motion.- Ephemerides and Navigating Space: Art from Rochester, New York, poses a fascinating question about the navigation of rockets and the possibility of creating ephemerides for faster-than-light travel. Fred explains the significance of ephemerides in celestial navigation while addressing the theoretical challenges of faster-than-light journeys.- Galactic Colors and Time Travel: David from Munich wonders about the different colors of galaxies captured by the James Webb Telescope and the implications of traveling to these distant realms. Fred discusses redshift, the nature of light, and how our view of the universe is essentially a glimpse into the past.- Heat and Friction in Space: Daryl from South Australia asks whether objects in space produce heat as they move. Fred clarifies the role of friction in a vacuum and the conditions under which objects can generate heat through their motion.For more Space Nuts, including our continually updating newsfeed and to listen to all our episodes, visit our website. Follow us on social media at SpaceNutsPod on Facebook, X, YouTube Music Music, Tumblr, Instagram, and TikTok. We love engaging with our community, so be sure to drop us a message or comment on your favorite platform.If you'd like to help support Space Nuts and join our growing family of insiders for commercial-free episodes and more, visit spacenutspodcast.com/aboutStay curious, keep looking up, and join us next time for more stellar insights and cosmic wonders. Until then, clear skies and happy stargazing.(00:00) Welcome to Space Nuts with Heidi Campo and Fred Watson(01:20) Discussion on time dilation and the speed of light(15:00) Navigating space with ephemerides(25:30) Exploring the colors of galaxies and time travel implications(35:00) Heat and friction in the vacuum of spaceFor commercial-free versions of Space Nuts, join us on Patreon, Supercast, Apple Podcasts, or become a supporter here: https://www.spreaker.com/podcast/space-nuts-astronomy-insights-cosmic-discoveries--2631155/support

Panelists: Dim, Andrew and ConTalking Points: Badoom TSCH, Tires (the show), Jon Lovitz, Relativity and Perception of age, Beverly Hills 90210, The 30s, Looking rich, ChatGPT, Dealing with the Post-Covid Era, Long service gifts, Ange Postecoglou, Banning the sale of Machetes, Useless Remakes in 2025, Timbaland & Tata, Ethical Streaming, Terrible 'Fun' Movies, Music to work to#oldtimey ##industry #timbaland #tata #ai #music #beatsbyai #metal #war #goldengirls #onlinesafety #scams #AI #immigration #machetes #cybersecurity #apple #streaming #netflix #amazonprime #hollywood #tires #news #melbourne #social #movies #thedukeleverageshow #instagram #spotify #podcast #itunespodcast #soundcloud #australia #newpodcast #podcaster #newepisodeIf you think you have a story to share or want to find a safespace to argue the pointless and the poignant, drop us a line at therealdukeleverage@gmail.com or DM us on the social media feeds. We're all about making dreams come true!https://linktr.ee/thedukeleverageshowDon't forget to hit the URL in the profile to get to our links. Make sure to like, share and follow and if you've listened to over 2 hours over 3 episodes you should keep our doors open and buy us a coffee!

Tonight we talk math, and strategy on the Wave Defense Battlepass and how to formulate your Section 31 Shopping list. Also, we look at the Relativity 4 weeks post F2P launch and how players are using it, and how they can earn more loot! 

SPONSORS: 1) GhostBed: Use Code "JULIAN" to get 10% off your new GhostBed Mattress https://ghostbed.com/julian PATREON: https://www.patreon.com/JulianDorey (***TIMESTAMPS in Description Below) ~ Claudia de Rham is a Swiss theoretical physicist working at the interface of gravity, cosmology, and particle physics. CLAUDIA's LINKS: IG: https://www.instagram.com/claudia.derham/ BUY HER BOOK: https://www.amazon.com/stores/author/B0CJRZY58B?ccs_id=a0ca1502-30a1-46da-b05d-d7bb911d44f9 FOLLOW JULIAN DOREY INSTAGRAM (Podcast): https://www.instagram.com/juliandoreypodcast/ INSTAGRAM (Personal): https://www.instagram.com/julianddorey/ X: https://twitter.com/julianddorey LISTEN to Julian Dorey Podcast Spotify ▶ https://open.spotify.com/show/5skaSpDzq94Kh16so3c0uz Apple ▶ https://podcasts.apple.com/us/podcast/trendifier-with-julian-dorey/id1531416289 ****TIMESTAMPS**** 00:00 - Claudia Dreams of Equations & Making Sense of World, Gravity 12:23 - String Theory 18:21 - String Theory Revelation (Holographic Projection) 30:04 - Exploring Emmy Noether's impact on physics 45:15 - What is Space & Time 52:52 - Black Holes 01:06:33 - Age of the Universe (Last Scattering) 01:19:08 - Meaning of Life (God Question) 01:26:03 - Growing Up Lack of Religion (Different Way of Thinking) 01:36:03 - Best Theory of Relativity & Universe, Dark Energy & Anti-Gravity 01:44:31 - DARPA Creating Anti-Gravity Science Theory 02:07:31 - Cosmic Dust 02:17:21 - Numerical Simulation 02:24:03 - Using AI in Science Today, Concept of Time (Time Travel) 02:35:19 - Astronaut Story 02:42:04 - Extraterrestrial Life 02:51:15 - Claudia's Projects CREDITS: - Host, Editor & Producer: Julian Dorey - COO, Producer & Editor: Alessi Allaman - https://www.youtube.com/@UCyLKzv5fKxGmVQg3cMJJzyQ Julian Dorey Podcast Episode 310 - Claudia de Rham Music by Artlist.io Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this insightful episode of the Lawyerist Podcast, we invite you to explore the profound interplay between personal resilience and professional advancement. Join business coach Sara Muender and host Zack Glaser as they guide us through the essential process of reframing failure and leveraging hardships for significant growth.  You'll discover how encountering obstacles or experiencing a dip in professional momentum often reveals deeper, underlying emotional dynamics. We underscore the critical importance of emotional intelligence and the strategic prioritization of human experience over purely technical or strategic solutions. Sara shares how AI tools, while invaluable for streamlining operations like project management, also provide significant support in mitigating overwhelm and burnout, allowing you to shift focus from mere tasks to your overall well-being.  This conversation offers a compelling perspective on navigating your unique challenges, emphasizing that genuine resilience stems from directly engaging with difficulties, not from avoiding them. We'll discuss why comparing your professional journey to others can be unproductive and how embracing even uncomfortable emotions can become a potent catalyst for your development. If you're seeking to cultivate a more robust understanding of your professional hurdles and harness emotional intelligence for sustained success, this episode provides invaluable guidance.    Have thoughts about today's episode? Join the conversation on LinkedIn, Facebook, Instagram, and X!    If today's podcast resonates with you and you haven't read The Small Firm Roadmap Revisited yet, get the first chapter right now for free! Looking for help beyond the book? See if our coaching community is right for you.    Access more resources from Lawyerist at lawyerist.com.  #516: Flexing Your Discipline Muscle to Stay Motivated, with Sara Muender  Apple Podcasts | Spotify | Lawyerist    #535: Lawyer Burnout: 5 Hidden Signs You're About to Crash, with Natasha Evans  Apple Podcasts | Spotify | Lawyerist    #506: Managing Stress & Avoiding Burnout, with Emily Nagoski  Apple Podcasts | Spotify | Lawyerist       Chapters:  00:00 - Introduction & AI's Role in Work  01:50 - AI for Project Scoping & Management  03:47 - AI, Client Feedback & Emotional Intelligence  04:40 - Overcoming Overwhelm with AI  07:10 - Finding "The Gift in the Struggle"  08:04 - Battling Burnout & Comparison Traps  13:53 - The Power of Slowing Down  16:11 - Embracing Failure & Building Resilience  22:29 - Failure as Data, Not Personal Worth  23:41 - Personal Tragedy & Finding Meaning  29:22 - The Relativity of Pain & Self-Improvement  34:35 - Facing Hard Truths & Growth 

In this insightful episode of the Lawyerist Podcast, we invite you to explore the profound interplay between personal resilience and professional advancement. Join business coach Sara Muender and host Zack Glaser as they guide us through the essential process of reframing failure and leveraging hardships for significant growth.  You'll discover how encountering obstacles or experiencing a dip in professional momentum often reveals deeper, underlying emotional dynamics. We underscore the critical importance of emotional intelligence and the strategic prioritization of human experience over purely technical or strategic solutions. Sara shares how AI tools, while invaluable for streamlining operations like project management, also provide significant support in mitigating overwhelm and burnout, allowing you to shift focus from mere tasks to your overall well-being.  This conversation offers a compelling perspective on navigating your unique challenges, emphasizing that genuine resilience stems from directly engaging with difficulties, not from avoiding them. We'll discuss why comparing your professional journey to others can be unproductive and how embracing even uncomfortable emotions can become a potent catalyst for your development. If you're seeking to cultivate a more robust understanding of your professional hurdles and harness emotional intelligence for sustained success, this episode provides invaluable guidance.    Have thoughts about today's episode? Join the conversation on LinkedIn, Facebook, Instagram, and X!    If today's podcast resonates with you and you haven't read The Small Firm Roadmap Revisited yet, get the first chapter right now for free! Looking for help beyond the book? See if our coaching community is right for you.    Access more resources from Lawyerist at lawyerist.com.  #516: Flexing Your Discipline Muscle to Stay Motivated, with Sara Muender  Apple Podcasts | Spotify | Lawyerist    #535: Lawyer Burnout: 5 Hidden Signs You're About to Crash, with Natasha Evans  Apple Podcasts | Spotify | Lawyerist    #506: Managing Stress & Avoiding Burnout, with Emily Nagoski  Apple Podcasts | Spotify | Lawyerist       Chapters:  00:00 - Introduction & AI's Role in Work  01:50 - AI for Project Scoping & Management  03:47 - AI, Client Feedback & Emotional Intelligence  04:40 - Overcoming Overwhelm with AI  07:10 - Finding "The Gift in the Struggle"  08:04 - Battling Burnout & Comparison Traps  13:53 - The Power of Slowing Down  16:11 - Embracing Failure & Building Resilience  22:29 - Failure as Data, Not Personal Worth  23:41 - Personal Tragedy & Finding Meaning  29:22 - The Relativity of Pain & Self-Improvement  34:35 - Facing Hard Truths & Growth  Learn more about your ad choices. Visit megaphone.fm/adchoices

The Daily Quiz - Science and Nature Today's Questions: Question 1: In which part of a plant does photosynthesis take place? Question 2: What type of rock is the hardest? Question 3: What Did Alfred Nobel Invent Before Initiating His Nobel Peace Prize Award Scheme? Question 4: Which of these does the prostate contribute to the production of? Question 5: Who proposed The Theory of Relativity? Question 6: What is solid carbon dioxide commonly known as? Question 7: What is the word for a male mouse? Question 8: Who discovered the structure of the atom? This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Lords, Ladies, and Theydies! By royal decree and under the ever-watchful eye of our potentate and monarch King Emmanuel Podcast IV, Esq. — prepare thyselves for a presence most prodigious and profound! Now entering the Bald & Beautiful Grand Hall of the Dolls...we present to you: the Duchess of Deadpan, the Empress of Eccentricities, the undisputed Queen of Comedy, KRISTEN SCHAAL! Follow Kristen: @k.schaal and check out Kristen's podcast at: https://www.youtube.com/@TheExtraordinarians Traveling this Summer? Find exactly what you're booking for at ⁠https://Booking.com⁠ Booking.YEAH! Book today on the site or in the app! Get the Rakuten app NOW and join the 17 million members who are already saving! Cash Back rates change daily, see https://Rakuten.com for details. Your Cash Back really adds up! This episode is sponsored by BetterHelp. Give online therapy a try at https://Betterhelp.com/BALD and get on your way to being your best self! To get 6 bottles of wine for $39.99, head to https://NakedWines.com/BALD and use code BALD for both the code AND password! If you're planning a trip this year, consider hosting your home on Airbnb while you're away. Your home might be worth more than you think! Find out how much at: https://Airbnb.com/host Follow Trixie: @TrixieMattel Follow Katya: @Katya_Zamo To watch the podcast on YouTube: ⁠⁠⁠⁠⁠http://bit.ly/TrixieKatyaYT⁠⁠⁠⁠⁠ To check out our official YouTube Clips Channel: ⁠⁠⁠⁠⁠https://bit.ly/TrixieAndKatyaClipsYT⁠⁠⁠⁠⁠ Don't forget to follow the podcast for free wherever you're listening or by using this link: ⁠⁠⁠⁠⁠https://bit.ly/thebaldandthebeautifulpodcast⁠⁠⁠⁠⁠ If you want to support the show, and get all the episodes ad-free go to: ⁠⁠⁠⁠⁠https://thebaldandthebeautiful.supercast.com⁠⁠⁠⁠⁠ If you like the show, telling a friend about it would be amazing! You can text, email, Tweet, or send this link to a friend: ⁠⁠⁠⁠⁠https://bit.ly/thebaldandthebeautifulpodcast⁠⁠⁠⁠⁠ To check out future Live Podcast Shows, go to: ⁠⁠⁠⁠⁠https://trixieandkatyalive.com⁠⁠⁠⁠⁠ To order your copy of our book, "Working Girls", go to: ⁠⁠⁠⁠⁠https://workinggirlsbook.com⁠⁠⁠⁠⁠ To check out the Trixie Motel in Palm Springs, CA: ⁠⁠⁠⁠⁠https://www.trixiemotel.com⁠⁠⁠⁠⁠ Listen Anywhere! ⁠http://bit.ly/thebaldandthebeautifulpodcast⁠   Follo​w Trixie: Official Website: ⁠https://www.trixiemattel.com/⁠ ​ Facebook: ​⁠https://www.facebook.com/trixiemattel⁠  Instagram: ⁠https://www.instagram.com/trixiemattel⁠ Twitter (X): ​⁠https://twitter.com/trixiemattel⁠   Follow Katya: Official Website: ⁠https://www.welovekatya.com/⁠ Facebook: ⁠https://www.facebook.com/welovekatya/⁠  Instagram: ⁠https://www.instagram.com/katya_zamo⁠  Twitter (X): ⁠https://twitter.com/katya_zamo⁠    About the Podcast: The Bald and the Beautiful with Trixie and Katya features a pair of grizzled gay ghouls sitting on chairs, holding microphones, and discussing their fabulous lives in Tinseltown. (featuring occasional forays into movies, television shows, and air-conditioning) The New York Times called them models, moguls, actors, influencers, drag queens, RuPaul's Drag Race contestants, and even humanoids. If one thing can be said about these two preternaturally gorgeous queens' podcast, it's that Trixie and Katya find the sheer, unadulterated beauty of pure insanity. Tune in every week to experience the auditory pleasure that is The Bald and the Beautiful with Trixie and Katya. #TrixieMattel #KatyaZamo #BaldBeautiful Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. John Sweetenham shares highlights from Day 5 of the 2025 ASCO Annual Meeting, including data from large trials in advanced malignant melanoma and mCSPC plus a new approach to first-line treatment for patients with multiple myeloma who are not transplant eligible. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 5 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. The selected abstracts from this final day of ASCO25 include important new data from large, randomized trials in patients with advanced malignant melanoma and patients with metastatic castration-sensitive prostate cancer, as well as a new approach to the first-line treatment of patients with multiple myeloma who are not transplant eligible.  Starting with LBA9500, this study was conducted in patients with completely resected stage III or IV malignant melanoma and compared the combination of relatlimab plus nivolumab versus nivolumab alone in this population. The study, named the RELATIVITY-098 trial, was presented by Dr. Georgina Long from the University of Sydney, Australia. In her introduction to the study, Dr. Long explained that the current standard of care for adjuvant therapy of resected stage III/IV melanoma is with PD-1 monotherapy with nivolumab, but that about 50% of patients will suffer from a subsequent relapse. In the first-line setting in patients with advanced or unresectable melanoma, the combination of nivolumab with the LAG-3 inhibitor, relatlimab, has been previously shown to improve progression-free survival in the RELATIVITY-047 trial. The current study evaluated this same combination in the adjuvant setting. More than 1,000 patients from 24 countries were randomized to receive either nivolumab alone (546 patients) or the combination of nivolumab with relatlimab (547 patients). Both treatments were given for a maximum of 1 year or until progression of disease, unacceptable toxicity, withdrawal, or death. Various biomarker studies were also undertaken including LAG-3 and PD-1 expression on CD8-positive T cells. The primary endpoint of the study was relapse-free survival, and Dr. Long reported that this was the same in both arms of the study. For example, at 24 months, the relapse-free survival was 64% in the monotherapy arm compared with 62% in the combination arm. The hazard ratio was 1.01 and the P value was 0.928. Metastasis-free survival was also identical in both arms. No benefit was observed for the combination in any of the prespecified subgroups. No new toxicity signals emerged compared with the RELATIVITY-047 trial. Interestingly, the baseline surface expression of LAG-3 and co-expression of LAG-3 and PD-1 on CD8 T cells in the 098 adjuvant trial were lower than in the 047 advanced disease trial, perhaps explaining why the combination did not confer benefit over nivo alone in the adjuvant setting. This is an important result, demonstrating that results from one clinical setting cannot always be extrapolated to another. Although the combination has gained some use in the adjuvant setting, this study clearly demonstrates that more drug in this situation is no better and that monotherapy remains the current standard of care. Results from the AMPLITUDE trial for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes, in LBA5006, were presented today by Dr. Gerhardt Attard from University College London, UK. This international, multicenter study evaluated the combination of the selective PARP inhibitor, niraparib, in combination with abiraterone acetate and prednisone. The same combination has been previously shown to improve outcomes in castration-resistant metastatic prostate cancer harboring BRCA mutations in the MAGNITUDE study. The current trial included patients with castration-sensitive disease with HRR mutations including BRCA1/2. Six hundred and ninety-six patients were randomized between niraparib, abiraterone, and prednisone plus androgen deprivation therapy, or the same combination with placebo instead of niraparib. Permitted prior therapies included no more than 6 months of prior androgen deprivation therapy and the use of docetaxel, or prior palliative radiation therapy. The primary endpoint of the study was radiographic relapse-free survival. Dr. Attard reported that the risk for radiographic progression-free survival in the whole population was significantly reduced by 37% with niraparib and abiraterone acetate plus prednisone compared with the placebo arm. The radiographic progression-free survival risk reduction with niraparib in the prespecified BRCA1/2 subgroup was 48% and reached statistical significance compared with the placebo arm. The secondary endpoint of time to symptomatic progression was also improved with niraparib in the HRR population and the BRCA1/2 subgroup. There was a trend for overall survival favoring the niraparib combination. However, the overall survival data were immature at this first interim analysis and did not yet reach statistical significance. No new safety concerns emerged with the toxicity data consistent with the MAGNITUDE study. Less than 5% more of the patients on the experimental arm discontinued treatment in comparison to the control arm. The authors conclude that the AMPLITUDE study results support the use of niraparib, abiraterone, and prednisone as a new treatment option for patients with metastatic castration- sensitive prostate cancer and BRCA and homologous recombination repair gene alterations. The results certainly support this conclusion and are potentially practice-changing. Turning to hematologic malignancies, my final selection from today's presentations is Abstract 7504, presented by Dr. Hang Quach from St Vincent's Hospital, Melbourne, Australia, and describes a novel combination of elranatamab, daratumumab, and lenalidomide in patients with newly diagnosed multiple myeloma who are not transplant-eligible – the so-called MagnetisMM-6 trial part 1. Elranatamab is a novel bispecific T-cell engaging antibody directed against BCMA and CD3, which has previously been approved for certain patients with relapsed and refractory multiple myeloma. In the present study, this was combined with lenalidomide and daratumumab in newly diagnosed patients. The report today describes the dose-finding phase of this study, which was part 1, specifically addressing so-called dose level ‘G', comprising elranatamab 76mg subcutaneously every 4 weeks plus daratumumab 1800mg subcutaneously and lenalidomide 25mg given orally. Thirty-seven patients were entered at this dose level, of whom 32 were on treatment at the time of analysis. Early response data show an overall response rate of 97.3%. With median follow up of 7.9 months, the current CR rate is 27% with a VGPR rate of almost 68%. The most frequent toxicities were hematologic, with neutropenia observed in 75%. Some cytokine release syndrome was observed in about 60% of patients, but none was greater than grade 2. The authors conclude that this combination is active in untreated multiple myeloma, with manageable toxicity and evidence of responses which appear to deepen over time. The dose-finding component of this trial is continuing and will subsequently progress into a phase 3 trial based on the data from the current study. This will compare daratumumab plus lenalidomide with the same combination plus elranatamab in previously untreated patients. That concludes our special coverage from the 2025 ASCO Annual Meeting. Thanks for listening and we hope you have enjoyed listening to our top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

In this episode I discuss the differences between intellectual definitions and emotional descriptions. I explain how they are used in continuation with the Law of Relativity.

In this episode I discuss the law of relativity. I explain how it builds on the foundation of the previous 8 laws.

Dr. West is a Harvard and Johns Hopkins-trained oncologist and researcher, and has advanced cancer care and research for over three decades. As a native of Memphis, Tennessee, Dr. West founded the West Clinic there in 1979, growing it from a single practice into a network of five locations with 25 physicians and 273 support staff, treating 300 to 400 patients weekly. As a Christian and lifelong member of one of the largest Methodist Churches in the U.S., he has lectured for more than forty years on the myth of science and faith being at odds, believing they support one another and that science reveals God. His book is called Sacred Science: Understanding Divine Creation.   Click here to purchase the book.

Send us comments, suggestions and ideas here! In this week's episode Heka Astra brings us full circle to conclude this three part series concerning the philosophy and occult implications found within Rudolph Steiner's Philosophy of Freedom. On the first side of the tape we discuss the philosophy of Monism and just how many concepts fit neatly inside of it and whether or not the world or life itself has a purpose. If so, where does it come from? In the extended show we wrap up all the loose ends and conclude with a rousing discussion on Steiner's ideas about morality, the imagination, the value of life itself, individuality, the genius, racial qualities (warning it gets controversial [not the views of the hosts!]) and answers, finally, once and for all, if we are truly free or not. Thank you and enjoy the show!This episode was written by Heka Astra with additional research and commentary by Luke Madrid and Mari Sama.In this week's episode we discuss: -The Philosophy of Monism-External Control-Moral Compulsion-Purpose and Destiny-Knowledge and Conversation With the HGAIn the extended show available at www.patreon/com/TheWholeRabbit we reach the enlightening conclusion and discuss:-Moral Imagination?-The Value of Life-Antiquated / Controversial Theories of Race From the Text-Individuality-The Final Consequences of Monism-We Are Free!Where to find The Whole Rabbit:Spotify: https://open.spotify.com/show/0AnJZhmPzaby04afmEWOAVInstagram: https://www.instagram.com/the_whole_rabbitTwitter: https://twitter.com/1WholeRabbitOrder Stickers: https://www.stickermule.com/thewholerabbitOther Merchandise: https://thewholerabbit.myspreadshop.com/Music By Spirit Travel Plaza:https://open.spotify.com/artist/30dW3WB1sYofnow7y3V0YoSources:The Philosophy of Freedom PDFhttps://argos.vu/wp-content/uploads/2018/11/Philosophy_of_Freedom-Rudolf_Steiner-4.pdfSupport the show

"Zen in Our Time" and "Connecting the Dots" are themes that I have hit upon for 2025, forming the thread running through (one meaning of "sutra") all of my DharmaByte newsletter columns and online UnMind podcasts this year. Contextualizing the teachings and legacy of Zen in modern times — without throwing the baby out with the bathwater — is key to transmitting Zen's legacy. Connecting the dots in the vast matrix of Dharma — while bridging the gap between 500 BC to 2025 CE in terms of the cultures, causes and conditions — is necessary to foster the evolution of Shakyamuni's Great Vow, from the closing verse of the Lotus Sutra's Lifespan Chapter: I am always thinking: by what means can I cause sentient beings to be able to enter the highest path and quickly attain the Dharma? As in so many aspects of our overloaded society, when contemplating the next column or podcast, the question always arises, "Where do I begin?" I turn to my collaborators — Hokai Jeff Harper, publisher of the newsletter, and Shinjin Larry Little, producer of the podcast — for clarity and inspiration. Jeff responded to my call for suggested topics with an intriguing trio: • To everything there is a season• The wax and wane of householder zazen practice• What we are feeling right now IS impermanence manifesting itself Instead of choosing one over the others, it occurred to me that all three are important. And they are interrelated, in a kind of fish-trap narrowing of focus, from the universal span of spacetime as a causal nexus for humankind; then homing in on the social level, considering the modern householder's vacillation in attempting to pursue what began long ago as a monastic lifestyle; and finally zeroing in on the personal: the intimacy of realization within the immediate flow of reality. I will attempt to treat them in succession over the next three installments, in the context of transmission of Zen's Original Mind. TO EVERYTHING THERE IS A SEASONIf you find the 1960s Pete Seeger song popularized by the Byrds running through your brain, you are not alone. If you recollect the poem from Ecclesiastes — which I studied in a unique, small-town high school literature course — you may be hearing echoes of: To every thing there is a season, and a time to every purpose under the heaven: A time to be born, and a time to die; a time to plant, and a time to pluck up that which is planted; A time to kill, and a time to heal; a time to break down, and a time to build up; A time to weep, and a time to laugh; a time to mourn, and a time to dance; A time to cast away stones, and a time to gather stones together; a time to embrace, and a time to refrain from embracing; A time to get, and a time to lose; a time to keep, and a time to cast away; A time to rend, and a time to sew; a time to keep silence, and a time to speak; A time to love, and a time to hate; a time of war, and a time of peace. Or from Tozan Ryokai: Within causes and conditions, time and season, IT is serene and illuminating And finally, from Dogen Zenji: Firewood becomes ash and it does not become firewood again.Yet do not suppose that the ash is future and the firewood past. You should understand that firewood abides in the phenomenal expression of firewood, which fully includes past and future, and is independent of past and future. Ash abides in the phenomenal expression of ash, which fully includes future and past.
 Just as firewood does not become firewood again after it is ash, you do not return to birth after death... Birth is an expression complete this moment; death is an expression complete this moment. They are like winter and spring; you do not call winter the "beginning" of spring, nor summer the "end" of spring. There are many more such incisive and insightful references to time in the literature of Zen, as well as Western thinking, of course, most notably Master Dogen's fascicle titled "Uji," which translates as something like "Being-time," "Existence-time," or "Living time," as Uchiyama-roshi renders it. This 13th Century writing is said to have anticipated the theory of Relativity, Einsteins' prodigious accomplishment, perhaps the most important scientific breakthrough of the 20th Century. But these few recollections from the rich legacy of Zen's written record will suffice for our purposes of connecting some of the dots in Indra's Net, or the modern components of the "Matrix of the Thus-Come One" as described in the Surangama Sutra. Scanning the Biblical poem, it is striking to see so many various activities and reactions to the obligations and behaviors of daily human life listed in equally dispassionate terms, not implying false equivalencies, but for example to blithely assert that there is "a time to kill" and "a time to heal"; "a time of war" and "a time of peace" — in the same breath — is in itself breathtaking, considering the admonition against killing, or murder, found in the Ten Commandments as well as the first Five Grave Precepts of Buddhism. Jumping to Master Tozan, or Dongshan, the founder of Soto Zen in 9th Century China, we find a hint of some resolution of the "whole catastrophe" in his reference to "IT" being "serene and illuminating," regardless of time and season, causes and conditions. This "it" appears in various Buddhist sayings and teachings, as tathata in Sanskrit — the inexpressible; or inmo in Japanese — the ineffable, the essential. These all point to what I analogize as a "singularity of consciouness" that emerges in zazen, where we pass the event horizon of conventional perception — the mind collapsing inward of its own mass — returning to and revealing our Original Mind, merging subject and object, duality and nonduality, in mokurai — the resolution of all apparent dichotomies. Earlier in Tozan's Precious Mirror Samadhi, or Hokyo Zammai, from which the above quote is taken, he magnifies the central place of this "it" in the experiential realm of Zen realization: Although IT is not constructed, IT is not beyond wordsLike facing a precious mirror, form and reflection behold each otherYou are not IT but in truth IT is you Master Dogen's coinage of "the backward step" captures this 180-degree attitude adjustment in the way we usually approach learning, self-improvement, and general development as human beings on the learning curve of reality. "From the very beginning all beings are buddhas," as Hakuin Zenji, 18th Century Rinzai Zen master, poet and artist states in the first line of his famous poem, "Song of Zazen." For every thing there may be a season, but when it comes to the most important thing in Buddhism, there is fundamentally no change — from beginning to middle to end — of this "poor player," life, strutting and fretting his/her hour upon the stage. In another line from Chinese Zen, the third Ancestor in 6th Century China captures this succinctly: Change appearing to occur in the empty world we call realonly because of our ignorance. So, somehow, once again, we are getting it all wrong, backwards. Our recourse is, of course, to get our butts back to the cushion; trust the original mind; take the backward step; and embrace the revolutionary notion that WE are not IT, but in truth IT is US. I cannot resist the urge to close this segment with one of my favorite quotes from the great Master Pogo: We have met the enemy and he is us. It may be a comfort to realize that "mine enemy grows older" as we age. We just have to outlive our enemies, including our own ignorance. Next month we will take up the second suggestion, the waxing and waning of householder zazen practice. Been there, done that.

Send us comments, suggestions and ideas here! In this week's episode we stack up behind Heka Astra who is leading the charge and authoring this three part series through the twisted jungle of Rudolph Steiner's wild mind as he establishes the philosophical framework proving the truth we all feel inside, that we, despite some compelling evidence otherwise, are in fact truly free beings possessed of our own divine will as it is laid out in exhausting detail in his seminal classic “The Philosophy of Freedom.” In part two of our tour of Steiner's work we explore the shortcomings of naive realism and critical idealism which are easier to understand than it first sounds. In the extended episode we discuss how the faculty of feeling corresponds to traditional Hermetic elemental associations, the nature of individuality, the limits of knowledge and the awesome power of the All-Mind or Nous. Make sure to tune in next week to see how it all combines to create a uniquely free spirit. Thank you and enjoy the show. This episode was written by Heka Astra with additional research and commentary by Luke Madrid and Mari Sama.In this week's episode we discuss: Critical Idealism vs. Naive RealismAbsolute IllusionismWhat is a Percept?What is a Concept?The Power of THINKING Parabola ThoughtsThe Power of INTUITIONHave You Ever Seen a “4?” In the extended episode available at www.patreon.com/TheWholeRabbit we go further into the classified domain and discuss:The Hermetic Association of WaterThe Unification of Thought and FeelingThought as a BridgeHuman Individuality Are There Limits To KnowledgeIn A Locked RoomPoimandresThe All Mind / Nous Where to find The Whole Rabbit:Spotify: https://open.spotify.com/show/0AnJZhmPzaby04afmEWOAVInstagram: https://www.instagram.com/the_whole_rabbitTwitter: https://twitter.com/1WholeRabbitOrder Stickers: https://www.stickermule.com/thewholerabbitOther Merchandise: https://thewholerabbit.myspreadshop.com/Music By Spirit Travel Plaza:https://open.spotify.com/artist/30dW3WB1sYofnow7y3V0YoSources:The Philosophy of Freedom PDFhttps://argos.vu/wp-content/uploads/2018/11/Philosophy_of_Freedom-Rudolf_Steiner-4.pdfSupport the show

“Incomprehensible guttural noises”The HeptapodsArrival is as difficult a movie to discuss in the limited space of our show notes as it is a truly great work of modern science fiction filmmaking. It's also virtually impossible to discuss without spoilers. Heck, we had trouble cramming our discussion of the central concepts of the film into  One of director Denis Villeneuve's crowning cinematic achievements (and almost certainly the thing that made us all realize that he might be the only director who would be able to get Dune right on screen), Arrival is an alien invasion movie unlike any other, one in which the humans don't cope with our new and strange looking neighbors with aggression, but rather by using science and reasoning to understand and communicate with them. Imagine that!You might fancy yourself a wiseacre and suggest the very notion of science and reasoning “does not fly” given the state of the world these days, but let's set that cynicism aside for the moment and get at the heart of this week's topic. Because in order to understand the way these aliens (the heptapods, not to be confused with Hakeem's ongoing Planet of the Cephalopods pitch) communicate via bizarre and smoky glyphs, humans are able to change their perception of time itself. You've heard of “perception determines reality” so get ready for “language affects perception which thus helps determine reality.” And if that sounds confusing, don't worry, because you've got Dr. Hakeem Oluseyi and Tamara Krinsky to hold your smoky hand (limb?) and walk you through it (forwards, backwards, and perhaps both at once). All of this and more is explored on a special, extra-sized episode of Does it Fly?...https://youtu.be/K_Duabt4f1s?si=9MGhHmj22EatyFQ8SUGGESTED VIEWING You mean you haven't seen Arrival? And you're watching and/or listening to this show? What's wrong with you! Go watch one of the most beautiful sci-fi movies of the last 25 years and THEN come back and hang out with us.FURTHER READING Do you want to delve a little deeper into the facts, concepts, and stories Hakeem and Tamara referenced in today's episode? Of course you do!Story of Your LifeArrival is based on a short story by Ted Chiang, called “Story of Your Life” which won the 1999 Hugo Award for Best Novella. It's available in a collection of Chiang's short stories, Stories of Your Life and Others.Relativity in ArrivalAlso known as the Sapir-Worf Hypothesis, based on the work of Edward Sapir and Benjamin Lee Whorf, but actually first stated as such Harry Hoijer in 1954. To quote Hoijer (via the Stanford Encyclopedia of Philosophy who have the most comprehensive explanation of this that we've been able to find): “language functions, not simply as a device for reporting experience, but also, and more significantly, as a way of defining experience for its speakers.” Arrival takes that to the next level by showing how it could define how we experience time itself! It also incorporates elements of the Many-Worlds theory, which we discussed in our Back to the Future episode!For extra credit, read up on Presentism, which postulates that only the current moment we live in is actual existence vs Eternalism, which states that our past AND future are equally real at all times. Then go take an Advil or something.The End of TimeNo, we're not talking about whatever horrors have you doomscrolling at the moment. It's Julian Barbour's book The End of Time: The Next Revolution in Our Understanding of the Universe, which argues that time as we know/perceive it, isn't really a thing.Speaking of time being an illusion…PsilocybinWe aren't endorsing anything, but…WANT MORE FROM DOES IT FLY?Speaking of some of the greatest sci-fi movies of the 21st Century, we'd like to remind you that Children of Men also exists and we dug into the disturbing real world implications of that movie right here.Andor season 2 is currently reminding people how good Star Wars can be when it actually has a conscience, so we took a look at the Star Wars franchise's most powerful and iconic megaweapon, the Death Star in one of our best episodes ever! FOLLOW US!Stay in the loop! Follow DoesItFly? on YouTube and TikTok and let us know what you think! Subscribe to Does It Fly? Pod: https://www.youtube.com/@doesitflypod?sub_confirmation=1And don't forget to follow Roddenberry Entertainment:Instagram: @RoddenberryOfficial Facebook: RoddenberryBluesky: @roddenberrypod.bsky.socialFor Advertising Inquiries: doesitfly@roddenberry.comCheck out the official Does it Fly? playlist, too!

Subscriber-only episodeIn this bonus episode, I share a raw and real moment from my own life as I navigate my separation. Change can feel messy, and it's also sacred. I reflect on how the Law of Relativity and the Law of Gestation have helped me stay anchored in truth and perspective. These universal laws remind us that nothing is inherently “bad,” and everything unfolds in divine timing. I'm in the thick of it, choosing to see the good and hold a vision for what's next. If you're in a season of uncertainty, this episode will hold you. Listen in.To listen to this episode, SUBSCRIBE to the Mystic Millionaire + for only $7/month and go deeper with me here: https://www.buzzsprout.com/818893/subscribeJoin the Mastering Your Mindset Facebook Group, and surround yourself with individuals who are on their journey to success. https://www.facebook.com/groups/MasteringYourMindsetwithDanielleWant to start working with me? Book a complimentary strategy call with The Success Society Team. We're here to support you. https://danielleamos.as.me/strategycallYou can catch the video version of this episode on my YouTube channel. Subscribe here: https://www.youtube.com/@thedanielleamosOne conversation with me can change your life. Access my free gift, Success Mindset Workshop, here: https://successmindsetworkshop.danielleamos.co/If you love this episode, please share it on Instagram, tag me, and send me a DM @TheDanielleAmos; I'd be so grateful if you could leave me a 5-star review on Apple Podcasts and Spotify. 

Send us comments, suggestions and ideas here! On this week's episode we follow our guide Heka Astra into the rarely explored yet vitally important philosophical conundrum of what it means to be free and if such a thing is even possible by exploring turn of the century occultist Rudolph Steiner's seminal classic on the subject, “The Philosophy of Freedom” which to the delight of the spiritually minded explains in, albeit exhaustive detail, the inner and outer workings of perception, will, thought and if or even how we may express our SUPPOSED God given right to freedom.  In the free side of the show we discuss what freedom even is, if it has anything to with choice (or not) and what Will has to do with the suit of wands in the Tarot. In the extended show we discuss the formation of the ego, the effect observation has on both light and our thoughts (we even yell about physics for a while) and the esoteric symbolism of the sword in the Hermetic tradition as it pertains to Steiner's explanation of thought. Thank you everybody and enjoy the show.In this week's episode we discuss: WTF is Freedom Anyway? Book of the Law StyleWhat is Determinism? Is Choice Free Will?Astrology and Free Will?To Will What one Wills…Esoteric Symbolism, The WandThe Power of ThinkingIn the extended show available at www.patreon.com/TheWholeRabbit we go further down the rabbit hole and continue discussing:The Formation of the EgoMonism vs. DualismMaterialismKhemetic WisdomThe Ace of Swords and ThinkingEinstein, Light and Relativity?The Conceptual RealmA Hobo in a Pear Tree Where to find The Whole Rabbit:Spotify: https://open.spotify.com/show/0AnJZhmPzaby04afmEWOAVInstagram: https://www.instagram.com/the_whole_rabbitTwitter: https://twitter.com/1WholeRabbitOrder Stickers: https://www.stickermule.com/thewholerabbitOther Merchandise: https://thewholerabbit.myspreadshop.com/Music By Spirit Travel Plaza:https://open.spotify.com/artist/30dW3WB1sYofnow7y3V0YoSourcesSteiner, Rudolph, The Philosophy of Freedomhttps://rsarchive.org/Books/GA004/English/RSP1964/GA004_index.htmlHeisenberg Uncertainty Principle:https://scienceexchange.caltech.edu/topics/quantum-science-explained/uncertainty-principle#:~:text=Formulated%20by%20the%20German%20physicist,about%20its%20speed%20and%20viceSupport the show

On this episode, we sit down with the brilliant and dynamic Dana Precious. From her humble start as a receptionist to holding top marketing positions at Sony, Marvel, and Relativity, Dana shares a story filled with humor, grit, and wisdom. Alongside her accomplishments in entertainment marketing, Dana is also a successful author of several novels, and in this episode, she reflects on creativity, leadership, industry changes, and personal evolution. What We Discuss: How Dana Precious transitioned from receptionist to CMO Lessons in navigating creative careers and studio politics Dana's insights on writing, brand strategy, and staying creatively inspired Her take on recent brilliant campaigns that others have done like Barbie and Oppenheimer Episode Highlights: [00:03:00] Dana's quirky entry into the industry and discovering copywriting [00:08:00] The power move (accidentally) that got her hired at Sony [00:28:00] Adjusting from agency life to studio marketing [00:46:00] Dana's writing career and genre-hopping storytelling [00:56:00] Why Barbie and Oppenheimer were marketing masterclasses [01:00:00] Her honest advice to young creatives trying to break in Featured Quotes: “Some of the best careers in this industry were started by people who were just terrible as receptionists.” – Corey Nathan “I discovered I was good at copywriting, and when people are good at something, they often discount it.” – Dana Precious “I always thought working hard and doing a good job was enough. But I didn't spend enough time making friends.” – Dana Precious Resources Mentioned: www.danapreciouswrites.com Our Sponsors:  The Golden Trailer Awards: goldentrailer.com/   Brent Allen Hagel: www.brentallenhagel.com Soundstripe: app.soundstripe.com Call to Action: Please leave us a rating and review:  https://apple.co/3QYy80e You can find Corey on all the socials @coreysnathan such as www.linkedin.com/in/coreysnathan. Want to hear how the best in the business craft the world's most exciting movie trailers? Tune in every week to Trailer Geeks and Teaser Gods!

At the start of last year, we had a really inspiring conversation with Chris Brown and are excited to reshare it this year, in our “Best Of” series. Originally published 01/25/24.An exceptional company culture builds when steadfast employee commitment meets deep trust by customers. Chris Brown encountered this when he joined Relativity as Chief Product Officer in 2018. Chris joined the team in the early stages of their transition to SaaS and embraced the moment of disruption and opportunity—a familiar territory in his career, which included ten years at Orbitz Worldwide. From the perspective of CPO, Chris offers unique insights into the transition period from on-prem to SaaS, addressing legacy technology, embracing the customer as a co-innovator by building plentiful touchpoints, and the intricate SaaS sales process. Speaking on what SaaS can inimitably provide, Chris muses on “a continuous stream of innovation at high availability” and customer success.In this episode, Chris looks ahead to the future to discuss how AI and LLMs will impact the law industry and finding effective uses for the technology. He shares how one of the oldest industries in the world can embrace the best of AI's capabilities while mitigating the risks by including the law's critical element: human decision-making and validation.With experience as a CEO and CPO, Chris shares the distinctions between the roles that stem from the needs of a particular company and offers how his arrival at Relativity reflected intentional scaling that led to further success. In discussing the Chicago startup environment and continued growth at Relativity, Chris talks about acquiring the contract review company Heretik and considering an acquisitive approach as one path of innovation and building a strong product portfolio. (02:24) – Introducing Chris Brown(04:56) – CPO vs. CEO(06:30) – Sales in the SaaS world(08:59) – Relativity(10:58) – Building an effective SaaS company(15:43) – Co-innovating with customers(17:59) – AI and the law industry(22:18) – Looking ahead(23:59) – An acquisitive approachChris Brown is the Chief Product Officer at Relativity, a cloud review software that helps users “organize data, discover truth, and act on it.” Previously, he served as Senior Vice President and Chief Product Officer at Orbitz Worldwide and CEO and Board Member of Kapow! Chris earned a bachelor's degree in computer engineering from the University of Illinois Urbana-Champagne.If you'd like to receive new episodes as they're published, please subscribe to Innovation and the Digital Enterprise in Apple Podcasts, Google Podcasts, Spotify, or wherever you get your podcasts. If you enjoyed this episode, please consider leaving a review in Apple Podcasts. It really

This year marks the 25th anniversary of socially conscious rapper Common's pivotal album Like Water for Chocolate. Hosts Jim DeRogatis and Greg Kot revisit their classic album dissection of Like Water for Chocolate including an interview with Common from the year 2000.Join our Facebook Group: https://bit.ly/3sivr9TBecome a member on Patreon: https://bit.ly/3slWZvcSign up for our newsletter: https://bit.ly/3eEvRnGMake a donation via PayPal: https://bit.ly/3dmt9lUSend us a Voice Memo: Desktop: bit.ly/2RyD5Ah Mobile: sayhi.chat/soundops Featured Songs:Common, "Time Travelin' (A Tribute to Fela)," Like Water for Chocolate, MCA, 2000Common, "Take it EZ," Can I Borrow a Dollar?, Relativity, 1992Common, "I Used to Love H.E.R.," Resurrection, Relativity, 1994Common, "Brown Sugar," Brown Sugar, EMI, 1995Common, "Funky for You," Like Water for Chocolate, MCA, 2000Common, "A Song for Assata," Like Water for Chocolate, MCA, 2000Common, "Payback is a Grandmother," Like Water for Chocolate, MCA, 2000Common, "The Light," Like Water for Chocolate, MCA, 2000Common, "The 6th Sense," Like Water for Chocolate, MCA, 2000Common, "Thelonius," Like Water for Chocolate, MCA, 2000Common, "Geto Heaven Remix T.S.O.I," Like Water for Chocolate (Alternate Edition), MCA, 2001Common, "A Film Called (Pimp)," Like Water for Chocolate, MCA, 2000Kendrick Lamar, "Institutionalized," To Pimp a Butterfly, Interscope, 2015New York Dolls, "Looking For a Kiss," New York Dolls, Mercury, 1973Delivery, "The New Alphabet," Force Majeure, Heavenly, 2025Delivery, "Deadlines," Force Majeure, Heavenly, 2025Lucy Dacus, "Ankles," Forever is a Feeling, Geffen, 2025See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textHe's only come back!Yes, Nord has returned, this time to give us his thoughts on a random would you rather question.We'd all love a super power right? What would it actually involve though and, with limitations, which would you pick?Find out what our dear friend and colleague Nord thinks in the latest episode of Socks: On or Off!Who Takes the Socks Off is now a part of the Channel 84 Podcast Network Family!Click here for more informationSupport the showHelp the Socks! Enjoying the episodes? You can help keep the mics on & the episodes flowing (if you can afford to). Head over to our Ko-Fi page & check out the options.Ko-Fi: https://ko-fi.com/sockspodSocialsTwitter: https://twitter.com/whotakesocksoffBlueSky: https://bsky.app/profile/socks.channel84.co.ukFacebook: https://www.facebook.com/whotakesthesocksoffInstagram: https://www.instagram.com/whotakesthesocksoffReview our thread count (5 stars only please, we're sensitive socks)Goodpods: https://goodpods.com/podcasts/who-takes-the-socks-off-204195Podchaser / iTunes: https://ratethispodcast.com/socksEverything ElseLinktree: https://linktr.ee/whotakesthesocksoffWe're part of the Studio:Channel84 Support Network.Studio: Channel 84 Network: ht...

Episode: 2447 The Special Theory of Relativity in Einstein's Own Words.  Today, simple but brilliant.

Physicist Matt Strassler drops in to talk about the origins of the universe and how we how what we know.About  our guest:Dr. Matt Strassler is a  theoretical physicist and writer. His research over the past thirty years has mainly been related mainly to the Large Hadron Collider, though he has written many papers on a wide variety of topics in string theory, quantum field theory and particle physics. He has recently completed a new book, called “Waves in an Impossible Sea“, in which, without assuming readers know any science or math, he explains modern physics and its centrality in human experience.

“The landscape we all stand on is shifting, and massive amounts of change are upon us,” Phil Saunders, the chief executive officer of e-discovery and legal technology giant Relativity, recently wrote in a post on the company's blog. Driving that change are three transformative forces, he wrote: new legal data challenges, advancing generative AI, and legal's journey to the cloud.  On this episode of LawNext, Saunders – who joined Relativity as CEO in 2022 after three decades in the technology sector – joins host Bob Ambrogi to discuss why he believes that both Relativity and the legal industry at large are at a pivotal moment, and to outline his company's vision for navigating these three forces reshaping the legal technology landscape.  Within Saunders' blog post was a notable announcement: Starting in 2028, Relativity will require that all new matters be hosted on its cloud platform, RelativityOne – a significant milestone for a company that built its success on its on-premises Relativity Server product.  The conversation starts there, with what might be considered the last mile in the company's transition to the cloud. Saunders also discusses what attracted him to join Relativity, how the company is approaching the opportunities and challenges presented by generative AI, its work with the Legal Data Intelligence initiative, and his longer-term strategic vision for Relativity.   Thank You To Our Sponsors This episode of LawNext is generously made possible by our sponsors. We appreciate their support and hope you will check them out.   Paradigm, home to the practice management platforms PracticePanther, Bill4Time, MerusCase and LollyLaw; the e-payments platform Headnote; and the legal accounting software TrustBooks. LEX Reception, Never miss a call, with expert answering service for Lawyers. Legalweek, March 24-27, New York Hilton Midtown. Register today at legalweekshow.com. Briefpoint, eliminating routine discovery response and request drafting tasks so you can focus on drafting what matters (or just make it home for dinner). If you enjoy listening to LawNext, please leave us a review wherever you listen to podcasts.  

This week we welcome Chan Hee-Koh, CEO and co-founder, and Justin Brownstone, Strategic Partnership Lead at FileRead. As legal professionals and tech enthusiasts gear up for LegalWeek, the conversation starts with some lighthearted banter about the best places to visit in New York—including a passionate endorsement of Angelina in Paris' hot chocolate. However, the discussion quickly turns toward the evolving role of AI in the legal industry and how FileRead is shaping the future of litigation technology.Chan shares the deeply personal story that inspired FileRead's creation: his immigrant family's experience during the 2008 housing crisis. Seeing how legal services were out of reach for many due to the complexity and cost of litigation, he set out to develop a platform that could make legal discovery and fact-finding more accessible and efficient. FileRead focuses on litigation-specific AI applications, aiming to streamline document review, build stronger factual narratives, and uncover hidden stories within vast amounts of case data. The discussion also touches on the industry's skepticism toward AI and the need for legal tech companies to build trust and demonstrate real value.The conversation then turns to FileRead's recent growth and roadmap for 2025. Having secured a $6 million seed funding round and a strategic partnership with Simplify, the company is expanding its capabilities beyond Relativity to offer a standalone AI-powered litigation analysis platform. Justin highlights how FileRead's technology goes beyond standard eDiscovery tools by enabling instant document analysis, chronology building, and memo drafting—tasks that traditionally take weeks of manual work. The team is also working on developing litigation workflows that will automate complex fact-checking processes, helping lawyers assess case strengths and identify missing evidence more efficiently.A key theme of the episode is the legal industry's slow but inevitable adoption of AI. Chan and Justin discuss how legal workflows are fundamentally different from those in other industries due to the uncertainty and unpredictability of litigation. Unlike transactional law, where contracts and compliance processes are more standardized, litigation involves a constantly shifting landscape where new evidence and legal arguments can completely change the direction of a case. The hosts and guests explore how AI is beginning to bridge the gap between human expertise and technological efficiency, making legal work more strategic and less burdened by repetitive document review.As the episode wraps up, the hosts reflect on the rapid evolution of legal technology. Greg and Marlene note that while AI has been discussed in legal tech for years, the capabilities of large language models (LLMs) have dramatically accelerated in just the last two years. Chan and Justin acknowledge that staying ahead in this fast-moving space requires constant experimentation and adaptation. However, they emphasize that while technology can enhance legal work, people remain at the center of the industry. AI should be seen as a tool that empowers attorneys rather than replaces them. To learn more about FileRead, visit FileRead.com, or reach out directly to Chan and Justin via email.Listen on mobile platforms:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Blue Sky: ⁠⁠@geeklawblog.com⁠⁠ ⁠⁠@marlgeb⁠⁠⁠⁠⁠⁠⁠Email: geekinreviewpodcast@gmail.comMusic: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jerry David DeCicca⁠⁠⁠⁠⁠⁠⁠⁠⁠Transcript

Eric Schmidt has taken a majority stake in Relativity and will serve as its CEO, so this is a good time to check in on their plans. Rocket Lab is planning to acquire Mynaric, and I have a theory I felt like I needed to float.This episode of Main Engine Cut Off is brought to you by 32 executive producers—Matt, Donald, Frank, David, Lee, Will and Lars from Agile, Kris, Pat from KC, Joel, Bob, The Astrogators at SEE, Joakim (Jo-Kim), Steve, Josh from Impulse, Tim Dodd (the Everyday Astronaut!), Warren, Better Every Day Studios, Ryan, Heiko, Joonas, Pat, Jan, Fred, Stealth Julian, Theo and Violet, Russell, and four anonymous—and hundreds of supporters.TopicsEric Schmidt Joins Relativity Space as C.E.O. - The New York TimesFormer Google CEO Eric Schmidt is the new leader of Relativity Space - Ars TechnicaRelativity Space makes significant progress on Terran R; flight hardware in production - NASASpaceFlight.comRelativity names Eric Schmidt as CEO as it updates Terran R development - SpaceNewsTo avoid the Panama Canal, Relativity Space is moving some operations to Texas - Ars TechnicaRocket Lab to expand into laser communications with Mynaric acquisition - SpaceNewsThe ShowLike the show? Support the show on Patreon or Substack!Email your thoughts, comments, and questions to anthony@mainenginecutoff.comFollow @WeHaveMECOFollow @meco@spacey.space on MastodonListen to MECO HeadlinesListen to Off-NominalJoin the Off-Nominal DiscordSubscribe on Apple Podcasts, Overcast, Pocket Casts, Spotify, Google Play, Stitcher, TuneIn or elsewhereSubscribe to the Main Engine Cut Off NewsletterArtwork photo by FireflyWork with me and my design and development agency: Pine Works

In episode 68 we explore themes of time, place, race and identity in BLITZ , the 2024 World War II drama written and directed by Academy and BAFTA-Award-winning filmmaker Steve McQueen. BLITZ is told from the unique perspective and epic journey of a 9-year-old biracial boy named George (played by newcomer Elliott Heffernan) whose mother sends him from London to safety in the English countryside. But George doesn't want to go to the countryside and be separated from his mother and grandfather Gerald (Paul Weller). Defiant and determined George makes his escape to return home to East London. Our guest, Tré Ventour-Griffiths, is a multiply-disabled historian, creative writer, and sociologist with interests in Black histories, race and disability, pop culture and insurgent politics. His PhD research uses creative storytelling methods to consider a multigenerational story of Caribbean Northants (Northamptonshire) Post-1942. ------TIMESTAMPS0:56 - Exploring Blitz World War 2 Historical Context3:44 - Introduction to Tré Ventour-Griffiths5:12 - Tré Ventour-Griffiths's Research and Scholarship15:10 - Time and Relativity in BLITZ25:33 - Black rural and town peoples in the UK29:42 - Generic Break30:18 History of Racial Hostilities in UK, Social, Economic and Sexual Policing43:55 - Empire Arcade -- Representation and Racism in British Culture and Art51:34 - Desire for Historical Representation of Black Children as Children54:30 - Where to Watch BLITZ56:17 - DisclaimerSUBSCRIBE to the podcast on your favorite podcast platformLISTEN to past past podcasts and bonus episodesSIGN UP for our mailing listSUPPORT this podcast  SHOP THE PODCAST on our affiliate bookstoreBuy us a Coffee! You can support by buying a coffee ☕ here — buymeacoffee.com/historicaldramasistersThank you for listening! 

ESI orders continue to grow and become more complex. There are certain strategies and areas to focus on depending on what side you're on.   In this podcast interview, the goal is to discuss new areas that become points of contention such as discovery on discovery, hyperlinked documents, and more.   Moderator:  @Chris Acosta - Director, eDiscovery Resources, Morrison Foerster   Speakers: @Andy Kim - eDiscovery Counsel, Munger, Tolles & Olson LLP @Cristin Traylor - Senior Director, AI Transformation & Law Firm Strategy, Relativity 

Is “now” just an illusion? Neil deGrasse Tyson and comic co-host Paul Mecurio answer questions on the Higgs Field, dark energy, and the feasibility of Dyson spheres with astrophysicist Hakeem Oluseyi.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/hubble-trouble-with-hakeem-oluseyi/Thanks to our Patrons Omar Video, Dan Carson, Joy Jack, Christine Bryant, Andrea Andrade, mahmoud hassan, Kyal Murray, Mercedes Dominguez, Christopher Rogalski, Eric De Bruin, Telmore, Gabe Ramshaw, James Edward Humphrey, Laurel Herbert, AJ Chambers, Bill WInn, Mayson Howell, Julianne Markow, Manthan Patel, Sonya Ponds, Depression Rawr, David Leys, Garon Devine, Vishal Ayeppun, BIIZZxGaming, Kurt Clark, Max Goldberg, Beth McDaniel, Shelby Staudenmaier, Kinnick Sutton, Jane von Schilling, Joanne karl, Walter Kinslow, and Eric Johnston for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus.

The future isn't something we wait for, it's something we shape with our thoughts, emotions, and actions. In this session, I explored how shifting our mindset, managing fear, and staying present can help us navigate uncertainty and create our desired future. By understanding the power of vibration, reframing fear as an opportunity, and committing to daily non-negotiables, we set the foundation for exponential growth. To join my next free Friday Training sessions, email me at david@dmeltzer.com

Our past can either be a weight that holds us back or a tool that propels us forward. In this episode, I explored how shifting our perception of past experiences can lead to greater success and fulfillment. By taking accountability, reframing setbacks as lessons, and embracing forgiveness, we create a mindset that fosters growth and resilience. True progress comes from learning, adapting, and applying these lessons to shape a brighter future. To join my next free Friday Training sessions, email me at david@dmeltzer.com

Hosts Josh and Jamie and special returning guest critic and author Violet Lucca discuss a double feature inspired by her new book "David Cronenberg: Clinical Trials" with one of his earliest inspirations in sci-fi paperback cover artist turned experimental filmmaker Ed Emshwiller's RELATIVITY (1966) and one of Cronenberg's more unloved and forgotten passion projects, the psychological drama SPIDER (2002) starring Ralph Fiennes as a Freudian schizophrenic whose subjective mind provides Cronenberg with dreamy and depressed experimental form of the film. Next week's episode is a patron-exclusive bonus episode on 90s Stephen King adaptations by horror legends: THE DARK HALF (1993) + THE MANGLER (1955), you can get access to that episode (and all past + future bonus episodes) by subscribing to our $5 tier on Patreon: www.patreon.com/sleazoidspodcast Intro // 00:00-15:53 RELATIVITY // 15:53-1:01:07 SPIDER // 1:01:07-1:56:36 Outro // 1:56:36-1:59:38 BUY VIOLET'S DAVID CRONENBERG BOOK: https://bookshop.org/p/books/david-cronenberg-clinical-trials-violet-lucca/21170132?ean=9781419771910 MERCH: www.teepublic.com/stores/sleazoids?ref_id=17667 WEBSITE: www.sleazoidspodcast.com/ Pod Twitter: twitter.com/sleazoidspod Pod Letterboxd: letterboxd.com/SLEAZOIDS/ Josh's Twitter: twitter.com/thejoshl Josh's Letterboxd: letterboxd.com/thejoshl Jamie's Twitter: twitter.com/jamiemilleracas Jamie's Letterboxd: letterboxd.com/jamiemiller

What type of time travel is in “A Christmas Carol”? Neil deGrasse Tyson and comedian Chuck Nice answer fan questions on time travel, paradoxes, and wormholes with theoretical physicist, Brian Greene. Did Ebenezer Scrooge get pulled through a wormhole?  (Originally Aired December 20, 2022)NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/past-present-future-time-travel-with-brian-greene/ Subscribe to SiriusXM Podcasts+ on Apple Podcasts to listen to new episodes ad-free and a whole week early.

Could you travel back in time through a wormhole? Neil deGrasse Tyson sits down with theoretical physicist and Nobel Laureate Kip Thorne to reflect on discovering gravitational waves with LIGO, the science in the movie Interstellar, black holes, and many more mysteries still yet to be answered.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Colin Michael Gregory, Robert Gehrig, Élysse, patricia pulvirenti, Joe DiFranco, Jesus Osvaldo Bonilla, Cory Martin, Therese Talbot, Kass, Willian Fee, Terrance Richards, J. Spencer Cook "Spencer", Marilyn Webster, Gary Snider, Diego urueta, Stephen, Randall Olson, tucker Coffin, bruce evans, sue ercreich, Fredrik Johansson, Jan Turley, Brian Falk, and Terry Hofmann for supporting us this week. Subscribe to SiriusXM Podcasts+ on Apple Podcasts to listen to new episodes ad-free and a whole week early.